Evidence map›Paper›PMID 31068339›Full record

ArticleEMBO molecular medicine2019

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization.

Vadim Le Joncour, Pauliina Filppu, Maija Hyvönen, Minna Holopainen, S Pauliina Turunen, Harri Sihto, Isabel Burghardt, Heikki Joensuu, Olli Tynninen, Juha Jääskeläinen and 4 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  6. Rapid cleavage of 6-[EJNMMI radiopharmacy and chemistry · 2025
    Article
  7. Article
  8. Article
  9. Pathophysiological role of histamine signaling and its implications in glioblastoma.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  10. Article
  11. Article
  12. The origin of brain malignancies at the blood-brain barrier.Cellular and molecular life sciences : CMLS · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Bivalent EGFR-Targeting DARPin-MMAE Conjugates.International journal of molecular sciences · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Vadim Le JoncourTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8153-8563
Pauliina FilppuTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Maija HyvönenTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Minna HolopainenHelsinki University Lipidomics Unit, Helsinki Institute of Life Science (HiLIFE) and Molecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.
S Pauliina TurunenResearch Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki, Finland.
Harri SihtoTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Isabel BurghardtDepartment of Neurology and Brain Tumour Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Heikki JoensuuTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Olli TynninenDepartment of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland.
Juha JääskeläinenKuopio University Hospital, Kuopio, Finland.
Michael WellerDepartment of Neurology and Brain Tumour Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Kaisa LehtiResearch Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki, Finland.
Reijo KäkeläHelsinki University Lipidomics Unit, Helsinki Institute of Life Science (HiLIFE) and Molecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.
Pirjo LaakkonenTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland Pirjo.laakkonen@helsinki.fi.ORCID 0000-0002-9620-095X
University of Helsinki · FIUniversity of Zurich · CHKuopio University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current clinical care of glioblastomas leaves behind invasive, radio- and chemo-resistant cells. We recently identified mammary-derived growth inhibitor (MDGI/

Indexed as

GlioblastomaIntracellular MembranesLysosomesAnimalsBiomarkers, TumorCell Line, TumorFatty Acid Binding Protein 3FemaleHeterograftsHumansMaleMiceNeoplasm InvasivenessNeoplasm ProteinsNeoplasm TransplantationPermeabilityBiomarkers, TumorFABP3 protein, humanFatty Acid Binding Protein 3Neoplasm ProteinsantihistaminegliomaLMPMDGIPUFA

Identifiers

PMID31068339
PMCPMC6554674
OpenAlexW2944047957

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.